Dr. Peter Stock is a transplant surgeon who specializes in kidney, liver and pancreas transplants. He is co-director of the Pancreatic Islet Cell Transplantation Program.

In his research, Stock studies body mechanisms that lead to transplant rejection when the donor and recipient are not genetically identical. He also studies chimerism (a therapy to prevent transplant rejection that uses the donor's bone marrow cells) and pancreatic islet cell transplantation (a procedure that can allow people with type 1 diabetes to discontinue insulin therapy).

Stock received his medical training at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992.

Stock is an active teacher and supervises surgical residents and fellows. He is a member of numerous professional and honorary societies.

  • Education

    University of Illinois School of Medicine, 1982

  • Residencies

    University of Minnesota Medical Center, General Surgery, 1990

  • Fellowship

    UCSF Medical Center, Transplant Surgery, 1992

  • Board Certifications

    Surgery, American Board of Surgery

  • Academic Title

    Professor

Kidney Transplant Center

400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143

Liver Transplant Program

400 Parnassus Ave., Third Floor
San Francisco, CA 94143

Pancreas Transplant Services

400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143

Selected research

Decorative Caduceus

Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Type 1 Diabetes

The primary objective is to test the hypothesis that co-transplantation of allogeneic PTG with adult pancreatic islets (derived from same deceased donor) in the IM site in people with Type 1 diabetes with functioning...

Recruiting

Decorative Caduceus

HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for...

The primary objective of this study is to determine if an HIV-infected deceased kidney donor (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications.

Recruiting

Decorative Caduceus

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

Maraviroc (MVC) is a type of HIV medicine called a CCR5 inhibitor. This study will evaluate the safety and tolerability of MVC in HIV-infected adults receiving a kidney transplant.

Recruiting

Share